Yesterday's market is today's road map.
Recent anemic results belie more promising future prospects.
The company can consolidate its lead if it overcomes some challenges.
Merck is likely to succeed in getting states to mandate HPV vaccination.
Despite a run-up in the stock, Covance may be in for yet another solid year.
Past advantages in fuel and labor expenses appear to be on the wane.
The company's EPS forecast is enticing, but is it enough to buy on?
High corn prices could allow Monsanto to raise seed prices and improve margins.
While it's no trailblazer, this new car model shows that the company is paying attention to the right things.
The rise and fall of the company's low-sugar kids' cereals illustrates the pitfalls of responding hastily to media frenzies.
Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure.
The stage could be set for budget shifts that will hurt some defense contractors and help others.
The company has to confront concerns over genetically modified foods soon if it hopes to keep growing.
A new feature allows users the chance to make the news.
Christian conservatives could have had something to do with Wal-Mart's November weakness.
The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.
The luxury goods purveyor looks poised to finish strong in fiscal 2007, but keeping up the pace will present a challenge.
Will more investment in drug development hurt profitability?
The company is not out of the woods yet, but some positive signs are emerging.
Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore.